Scilex Holding Company (SCLX) Stock
SCLX Key Statistics
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
CEO: Henry H. Ji. Company website
SCLX — Frequently Asked Questions
What is the SCLX stock price today?
Scilex Holding Company (SCLX) trades at $10.33, up 28.00% on the day, as of Sep 20, 2026 15:00 UTC.
What is Scilex Holding Company's market cap?
Scilex Holding Company has a market capitalisation of $87.73M, calculated from the live SCLX share price and shares outstanding.
What is the P/E ratio of SCLX?
SCLX has no meaningful price-to-earnings ratio: Scilex Holding Company lost $34.85 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Scilex Holding Company make?
Scilex Holding Company generated revenue of $30.25M over the trailing twelve months, which puts the stock at 2.90 times sales.
What is the 52-week range for SCLX?
SCLX has traded between $3.46 and $11.88 over the past 52 weeks, and the last price is 13.0% below that high.
Is Scilex Holding Company profitable?
No. Scilex Holding Company is loss-making, with a net margin of -1,330.40% over the trailing twelve months.
What is the analyst price target for SCLX?
Wall Street analysts rate SCLX Buy.
What sector is Scilex Holding Company in?
Scilex Holding Company is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in US .
Who is the CEO of Scilex Holding Company?
Henry H. Ji is the chief executive of Scilex Holding Company, which employs 115 people.
Where can I track SCLX in real time?
QFI Terminal shows SCLX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SCLX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SCLX in Terminal See plans